GLYCOSYLATED HEMOGLOBIN HBA1C AS A MARKER OF GLYCEMIC STATUS AND DYSLIPIDEMIA IN DIABETES MELLITUS

2020 ◽  
pp. 29-33
Author(s):  
OJS Admin
Keyword(s):  
Diabetes Mellitus ◽  
Glycemic Control ◽  
Protein Metabolism ◽  
Metabolic Disorders ◽  
Glycated Hemoglobin ◽  
Glycosylated Hemoglobin ◽  
Glycemic Status

Diabetes mellitus is a group of metabolic disorders that cause hyperglycemia due to underutilization or e x c e ssi v e g l u c o s e a c c umu l a ti o n . Li p i d , carbohydrates and protein metabolism abnormalitiesoccur due to insulin dysfunction. Glycated hemoglobin (HbA1c) is a routinely used marker for long-term glycemic control.

scholarly journals The insulin resistance indices: necessity and opportunities in type 2 diabetes mellitus management

2020 ◽  
Vol 96 (7) ◽  
pp. 529-535
Author(s):  
Yu. A. Sorokina ◽  
O. V. Zanozina ◽  
A. D. Postnikova
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Clinical Practice ◽  
Glycemic Control ◽  
Metabolic Disorders ◽  
Glycosylated Hemoglobin ◽  
Tissue Sensitivity

The article provides a review of the literature on the possibilities of using various indices of insulin resistance in type 2 diabetes (T2DM) treatment. The main mechanisms of insulin resistance and its role in the formation of type 2 diabetes mellitus and other metabolic disorders are described. The main indices of insulin resistance, used in real clinical practice nowadays, are considered. Methods of their calculation are given. The effect of metformin and incretin active medications on insulin resistance is described. It was shown that the combination of these medications improves tissue sensitivity to insulin in patients with T2DM. Standard indicators for assessing glycemic control, such as fasting glucose and glycosylated hemoglobin (HbA1c), do not reflect the patient’s lipid metabolism. The use of insulin resistance assessment indices in patients with type 2 diabetes mellitus allows both, exercising glycemic control, and the metabolic disorders, often associated with carbohydrate metabolism disorders, monitoring. Using insulin resistance indices, it is possible to select the optimal treatment regimen for type 2 diabetes mellitus for a particular patient, to predict and evaluate the effectiveness of treatment in dynamics. Simple, generally available laboratory indicators and anthropometric data are used to calculate the indices of insulin resistance, and they are easy to measure. In this regard, the use of insulin resistance indices is possible in routine clinical practice.

scholarly journals RISK FACTORS OF TYPE 2 DIABETES MELLITUS DURATION AND NON-COMPLIANCE WITH MEDICATION TO POOR GLYCEMIC STATUS

2020 ◽  
Vol 8 (3) ◽  
pp. 256
Author(s):  
Marisa Gita Putri ◽  
K. Heri Nugroho HS ◽  
Mateus Sakundarno Adi ◽  
Suhartono Suhartono ◽  
Bagoes Widjanarko
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycosylated Hemoglobin ◽  
Exclusion Criterion ◽  
Glycemic Status ◽  
Type 2 Dm

Background: Type 2 diabetes mellitus is a chronic disease that is still a global health problem. Uncontrolled diabetes mellitus (DM) can result in poor glycemic status, with factors that affect patients including long-term DM and medication compliance. Purpose: This study aimed to determine the risk factors of long-term DM and non-compliance with medication on the poor glycemic control status of patients with type 2 DM. Methods: This type of research used observational analysis with a case–control design. Samples were taken from patients with type 2 DM, with 40 cases and 40 controls. The criteria for sample inclusion were that the patients had a glycosylated hemoglobin level check, were willing to be research respondents, and could communicate well. The exclusion criterion was patients experiencing a drastic decline in health status during the study. The sampling technique used was consecutive sampling. This research was conducted at the Panti Wilasa Citarum Hospital in Semarang City from July to September 2019. The relationship and the risk of long-term DM and adherence to taking medication with glycemic status were tested using the chi-square test. Results: This study showed that a duration of DM >5 years (p = 0.01; Odss Ratio (OR) = 3.46; 95% confidence interval [CI] = 1.37 < OR < 8.69) and non-compliance with taking medication (p = 0.02; OR = 3.15; 95% CI = 1.25 < OR < 7.93) are risk factors for poor glycemic status. Conclusion: Duration of DM >5 years and non-compliance with taking medication are risk factors for poor glycemic status in patients with type 2 DM.

Effects of long-term optimization and short-term deterioration of glycemic control on glucose counterregulation in type I diabetes mellitus

Diabetes ◽  
1984 ◽  
Vol 33 (4) ◽  
pp. 394-400 ◽  
Author(s):  
G. Bolli ◽  
P. De Feo ◽  
S. De Cosmo ◽  
G. Perriello ◽  
G. Angeletti ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Glycemic Control ◽  
Type I Diabetes ◽  
Type I Diabetes Mellitus ◽  
Type I ◽  
Short Term

scholarly journals Plasmatic Magnesium Deficiency in 101 Outpatients Living with Type 2 Diabetes Mellitus

2021 ◽  
Vol 11 (4) ◽  
pp. 791-800
Author(s):  
Hajer Zahra ◽  
Olfa Berriche ◽  
Ramla Mizouri ◽  
Fatma Boukhayatia ◽  
Marwa Khiari ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Glycemic Control ◽  
Magnesium Deficiency ◽  
Magnesium Level ◽  
Peripheral Artery ◽  
The Mean ◽  
Magnesium Status ◽  
Artery Disease

(1) Background: Magnesium deficiency is usually associated with type 2 diabetes mellitus (T2DM). Individuals living with T2DM with hypomagnesemia show a more rapid disease progression and have an increased risk for diabetes complications. (2) Methods: This is a cross-sectional and descriptive study in the National Institute of Nutrition and Food Technology of Tunis in Tunisia, including all adult outpatients (≥18 years old) with a diagnosis of T2DM from 1 September 2018 to 31 August 2019. The aim of this study was to evaluate the prevalence of plasmatic magnesium deficiency in a Tunisian population of T2DM and to study the relationship between magnesium status and intake, glycemic control and long-term diabetes-related complications. (3) Results: Among the 101 T2DM outpatients, 13 (12.9%) presented with a plasmatic magnesium deficiency. The mean age was 56 ± 7.9 years with a female predominance (62%, n = 63). The mean of the plasmatic magnesium level was 0.79 ± 0.11 mmol/L (0.5–1.1), and the mean of 24 h urinary magnesium excretion was 87.8 ± 53.8 mg/24 h [4.8–486.2]. HbA1c was significantly higher in the plasmatic magnesium deficiency group than the normal magnesium status group (10% ± 1.3 vs. 8.3% ± 1.9; p = 0.04), with a significant difference in participants with a poor glycemic control (HbA1c > 7%) (100%, n = 13/13 vs. 53%, n = 47/88; p = 0.001). A weak negative relationship was also found between plasmatic magnesium and HbA1c (r = −0.2, p = 0.03). Peripheral artery disease was more commonly described in individuals with low plasmatic magnesium levels than in individuals with normal levels (39%, n = 5 vs. 0%, n = 0; p < 0.001). The mean plasmatic magnesium level in participants without diabetic nephropathy and also peripheral artery disease was significantly higher compared to individuals with each long-term diabetes-related complication (0.8 mmol/L ± 0.1 vs. 0.71 mmol/L ± 0.07; p = 0.006) and (0.8 mmol/L ± 0.1 vs. 0.6 mmol/L ± 0.08; p < 0.001), respectively. (4) Conclusions: Hypomagnesemia was identified in individuals with T2DM, causing poor glycemic control and contributing to the development and progression of diabetes-related microvascular and macrovascular complications.

Sign in / Sign up

Export Citation Format

Share Document